Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of

  • 30 kg/m2 or greater (obese), or
  • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

 

DOSAGE AND ADMINISTRATION

General Dosing And Administration

In adults with an initial BMI of 30 kg/m2 or greater or 27 kg/m2 or greater when accompanied by weight-related co-morbidities such as hypertension, type 2 diabetes mellitus, or dyslipidemia prescribe Qsymia as follows:

  • Take Qsymia once daily in the morning with or without food. Avoid dosing with Qsymia in the evening due to the possibility of insomnia.
  • Start treatment with Qsymia 3.75 mg/23 mg (phentermine 3.75 mg/topiramate 23 mg extended-release) daily for 14 days; after 14 days increase to the recommended dose of Qsymia 7.5 mg/46 mg (phentermine 7.5 mg/topiramate 46 mg extended-release) once daily.
  • Evaluate weight loss after 12 weeks of treatment with Qsymia 7.5 mg/46 mg.

    If a patient has not lost at least 3% of baseline body weight on Qsymia 7.5 mg/46 mg, discontinue Qsymia or escalate the dose, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss at the Qsymia 7.5 mg/46 mg dose.

    To escalate the dose: Increase to Qsymia 11.25 mg/69 mg (phentermine 11.25 mg/topiramate 69 mg extended-release) daily for 14 days; followed by dosing Qsymia 15 mg/92 mg (phentermine 15 mg/topiramate 92 mg extended-release) once daily.

  • Evaluate weight loss following dose escalation to Qsymia 15 mg/92 mg after an additional 12 weeks of treatment.

    If a patient has not lost at least 5% of baseline body weight on Qsymia 15 mg/92 mg, discontinue Qsymia as directed, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.

  • Qsymia 3.75 mg/23 mg and Qsymia 11.25 mg/69 mg are for titration purposes only.

 

SIDE EFFECTS

The following important adverse reactions are described below and elsewhere in the labeling:

  • Fetal Toxicity: 
  • Elevation in Heart Rate 
  • Suicidal Behavior and Ideation 
  • Acute Angle Closure Glaucoma
  • Mood and Sleep Disorders
  • Cognitive Impairment 
  • Metabolic Acidosis 

Qsymia (Phentermine-Topiramate)

$360.00Price
Quantity

    Contact Us

    Philadelphia, PA, 19139

    peoplesmedshop@gmail.com

    • White Twitter Icon
    • White Facebook Icon

    Customer Service

    Contact Us

    Policy>

    Term of use>

    We Accept

    © Copywrite 2020 Peoplesmedshop.com | All Rights Reserved